Waldemar Priebe
Known title: 10% OwnerCIK: 0001678516
Associated companies
Transaction History
| CNSP | ▼ Sell | Open Market | 10,000 | $10K | 3/28/2023 | View on chart |
| CNSP | ▼ Sell | Open Market | 5,000 | $5K | 3/27/2023 | View on chart |
| CNSP | ▼ Sell | Open Market | 5,000 | $5K | 3/24/2023 | View on chart |
| CNSP | ▼ Sell | Open Market | 10,000 | $11K | 3/23/2023 | View on chart |
| CNSP | ▼ Sell | Open Market | 5,000 | $5K | 3/22/2023 | View on chart |
| CNSP | ▼ Sell | Open Market | 5,000 | $6K | 3/21/2023 | View on chart |
| CNSP | ▼ Sell | Open Market | 5,000 | $5K | 3/20/2023 | View on chart |
| CNSP | ▼ Sell | Open Market | 5,000 | $6K | 3/17/2023 | View on chart |
| CNSP | ▼ Sell | Open Market | 5,000 | $6K | 3/16/2023 | View on chart |
| CNSP | ▼ Sell | Open Market | 5,000 | $6K | 3/15/2023 | View on chart |
| CNSP | ▼ Sell | Open Market | 5,000 | $7K | 3/14/2023 | View on chart |
| CNSP | ▼ Sell | Open Market | 5,000 | $7K | 3/13/2023 | View on chart |
| CNSP | ▼ Sell | Open Market | 5,000 | $6K | 3/10/2023 | View on chart |
| CNSP | ▼ Sell | Open Market | 2,798 | $7K | 12/9/2022 | View on chart |
| CNSP | ▼ Sell | Open Market | 5,500 | $13K | 12/8/2022 | View on chart |
| CNSP | ▼ Sell | Open Market | 5,500 | $14K | 12/7/2022 | View on chart |
| CNSP | ▼ Sell | Open Market | 5,500 | $14K | 12/6/2022 | View on chart |
| CNSP | ▼ Sell | Other | 1,495,867 | — | 5/5/2020 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
CNS Pharmaceuticals Holds Shareholder/Analyst Call
On the call, CNS Pharmaceuticals shared recent developments and future plans. The session provided detailed updates for shareholders and analysts. The transcript offers insights into the company’s current focus and outlook.
CNS Pharmaceuticals Holds Shareholder/Analyst Call. On the call, CNS Pharmaceuticals shared recent developments and future plans. The session provided detailed updates for shareholders and analysts. The transcript offers insights into the company’s current focus and outlook.